---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000112"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:40:38.191228+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie terminates collaboration with Caribou for two allogeneic CAR-T programs; effective Oct 25, 2023

## Summary
- AbbVie exercised termination for convenience, citing strategic focus; not related to Caribou's performance or data.
- Termination effective October 25, 2023; all licenses under the 2021 Collaboration and License Agreement will end.
- Two preclinical allogeneic CAR-T programs targeting a single cancer target or target combination will be discontinued.
- No financial terms of termination disclosed; Caribou loses potential milestones and royalties from AbbVie programs.
- Caribou retains its Cas12a chRDNA genome-editing and CAR-T technologies for other partnerships.

## SEC filing metadata
- accession: 0001619856-23-000112
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000112/0001619856-23-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000112/crbu-20230926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000112
- JSON: https://secwatch.observer/filing/0001619856-23-000112.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000112.txt

## Key facts
- Material Agreements
  Caribou Biosciences, Inc. terminated Collaboration and License Agreement with AbbVie Manufacturing Management Unlimited Company valued at Agreement terminated for convenience by AbbVie (effective 2023-10-25).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: AbbVie Manufacturing Management Unlimited Company
  - Value: Agreement terminated for convenience by AbbVie
  - Effective: 2023-10-25
  source text: On September 26, 2023, Caribou Biosciences, Inc. (the “Company”) received notice from AbbVie Manufacturing Management Unlimited Company (“AbbVie”) that AbbVie has elected to terminate the Collaboration and License Agreement, as amended, by and between the Company and AbbVie, dated February 9, 2021 (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000112/0001619856-23-000112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.